Vertex Pharmaceuticals Incorporated · MUN:VX1

Vertex Pharmaceuticals Incorporated financial statements

Vertex Pharmaceuticals Incorporated's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue12.0B11.0B9.87B8.93B7.57B6.21B4.16B3.05B2.49B1.70B
Cost of revenue1.65B1.53B1.26B1.08B904.2M736.3M547.8M409.5M275.1M210.5M
Gross profit10.3B9.49B8.61B7.85B6.67B5.47B3.62B2.64B2.21B1.49B
Research and development3.91B3.63B3.16B2.54B3.05B1.83B1.75B1.42B1.32B1.05B
Selling, general and administrative1.75B1.46B1.14B944.7M840.1M770.5M658.5M557.6M496.1M432.8M
Operating income4.17B-232.9M3.83B4.31B2.78B2.86B1.20B635.1M123.2M9.94M
Depreciation and amortization209.8M207.2M181.3M148.3M125.6M109.5M106.9M72.4M61.4M61.4M
EBITDA4.38B-25.7M4.01B4.46B2.91B2.97B1.30B707.6M184.6M71.3M
Interest expense13.3M30.6M44.1M54.8M58.2M58.5M72.5M69.3M
Income before tax4.64B248.5M4.38B4.23B2.73B3.12B1.39B600.2M-15.7M-67.4M
Income tax690.0M784.1M760.2M910.4M388.3M405.2M218.1M-1.49B-107.3M16.7M
Net income3.95B-535.6M3.62B3.32B2.34B2.71B1.18B2.10B263.5M-112.1M
Earnings per share, basic15.46-2.0814.0512.979.0910.444.588.241.06-0.46
Earnings per share, diluted15.32-2.0813.8912.829.0110.294.518.091.04-0.46

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents5.08B4.57B10.4B10.5B6.79B5.99B3.11B2.65B1.67B1.18B
Short-term investments1.52B1.55B849.2M274.5M729.9M670.7M699.0M518.1M423.3M
Receivables2.05B1.61B1.56B1.44B1.14B885.4M633.5M409.7M281.3M200.4M
Inventory1.69B1.21B738.8M460.6M353.1M280.8M167.5M124.4M111.8M77.6M
Current assets11.2B9.60B14.1B13.2B9.56B8.13B4.82B3.84B2.65B1.83B
Property, plant and equipment745.1M812.0M789.4M698.4M
Goodwill1.09B1.09B1.09B1.09B1.00B1.00B1.00B50.4M50.4M50.4M
Total assets25.6B22.5B22.7B18.2B13.4B11.8B8.32B6.25B3.55B2.90B
Accounts payable461.7M413.0M364.9M303.9M195.0M155.1M87.6M111.0M74.0M61.5M
Current liabilities3.86B3.56B3.55B2.74B2.14B1.88B1.33B1.12B807.3M792.5M
Long-term debt0
Total debt0
Total liabilities6.98B6.12B5.15B4.24B3.33B3.06B2.23B1.81B1.50B1.56B
Shareholders' equity18.7B16.4B17.6B13.9B10.1B8.69B6.09B4.44B2.03B1.16B
Shares outstanding254.0M256.9M257.7M257.0M254.5M259.9M259.0M255.2M253.3M248.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations3.63B-492.6M3.54B4.13B2.64B3.25B1.57B1.27B844.9M236.1M
Capital spending-437.6M-297.7M-200.4M-204.7M-235.0M-259.8M-75.4M-95.4M-99.4M-56.6M
Free cash flow3.19B-790.3M3.34B3.93B2.41B2.99B1.49B1.17B745.5M179.5M
Cash from investing-945.4M-3.77B-3.14B-321.1M-340.9M99.4M-1.24B-202.2M-483.3M51.2M
Cash from financing-2.26B-1.49B-562.2M-67.7M-1.48B-505.3M126.8M-71.2M68.4M133.3M
Share buybacks-2.02B-1.18B-427.6M0-1.43B-539.1M-186.0M-350.0M00
Change in cash515.6M-5.80B-139.7M3.71B811.2M2.87B462.4M990.7M435.8M415.9M